

# Hugh Barrett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8723940/publications.pdf>

Version: 2024-02-01

206  
papers

9,395  
citations

30070  
54  
h-index

54911  
84  
g-index

206  
all docs

206  
docs citations

206  
times ranked

8487  
citing authors

#	ARTICLE	IF	CITATIONS
1	Unravelling lipoprotein metabolism with stable isotopes: tracing the flow. <i>Metabolism: Clinical and Experimental</i> , 2021, 124, 154887.	3.4	7
2	PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a). <i>Metabolism: Clinical and Experimental</i> , 2020, 107, 154221.	3.4	46
3	Apolipoprotein(a) Kinetics in Statin-Treated Patients With Elevated Plasma Lipoprotein(a) Concentration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6247-6255.	3.6	16
4	Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 8-11.	3.4	10
5	Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy. <i>Journal of the American Heart Association</i> , 2019, 8, e011781.	3.7	40
6	Differential Effects of Estrogen and Progesterone on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women. <i>Lipids</i> , 2018, 53, 167-175.	1.7	7
7	Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR <sup>-/-</sup> ) and LDLR <sup>-/-</sup> Tg ETQq1 1 0.784314 rgBT / Overlock 1178-1190.	2.4	35
8	Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. <i>European Heart Journal</i> , 2018, 39, 2577-2585.	2.2	116
9	Acute Impact of Different Exercise Modalities on Arterial and Platelet Function. <i>Medicine and Science in Sports and Exercise</i> , 2018, 50, 785-791.	0.4	4
10	Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease. <i>European Journal of Clinical Investigation</i> , 2018, 49, e13053.	3.4	11
11	Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque. <i>Atherosclerosis</i> , 2018, 275, 232-238.	0.8	21
12	Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1644-1655.	2.4	30
13	Personal model-assisted identification of NAD <sup>+</sup> and glutathione metabolism as intervention target in NAFLD. <i>Molecular Systems Biology</i> , 2017, 13, 916.	7.2	147
14	Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin. <i>Journal of Lipid Research</i> , 2017, 58, 1315-1324.	4.2	44
15	Tamoxifen reduces hepatic VLDL production and GH secretion in women: a possible mechanism for steatosis development. <i>European Journal of Endocrinology</i> , 2017, 177, 137-143.	3.7	25
16	Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism. <i>Circulation</i> , 2017, 135, 338-351.	1.6	80
17	Impact of commonly prescribed exercise interventions on platelet activation in physically inactive and overweight men. <i>Physiological Reports</i> , 2016, 4, e12951.	1.7	3
18	Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a). <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 381-390.	3.4	37

#	ARTICLE	IF	CITATIONS
19	Modeling the Male Reproductive Endocrine Axis: Potential Role for a Delay Mechanism in the Inhibitory Action of Gonadal Steroids on GnRH Pulse Frequency. <i>Endocrinology</i> , 2016, 157, 2080-2092.	2.8	13
20	Impact of a Digital Activity Tracker-Based Workplace Activity Program on Health and Wellbeing. , 2016, ,		15
21	Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 1140-1145.	2.6	19
22	Ω-3 Fatty Acid Ethyl Esters Diminish Postprandial Lipemia in Familial Hypercholesterolemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3732-3739.	3.6	29
23	Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III. <i>European Journal of Clinical Investigation</i> , 2016, 46, 730-736.	3.4	9
24	Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism. <i>Current Opinion in Lipidology</i> , 2016, 27, 550-556.	2.7	5
25	Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 384-391.	4.4	10
26	ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1398-1406.	3.6	4
27	Lipoprotein metabolism in an apoB-80 familial hypobetalipoproteinemia heterozygote. <i>Clinical Biochemistry</i> , 2016, 49, 720-722.	1.9	2
28	Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults. <i>Heart Lung and Circulation</i> , 2016, 25, 520-525.	0.4	50
29	Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1484-E1490.	3.6	6
30	Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2218-2224.	2.4	58
31	Effect of Dietary Fatty Acids on Human Lipoprotein Metabolism: A Comprehensive Update. <i>Nutrients</i> , 2015, 7, 4416-4425.	4.1	101
32	Inter-relationships between proprotein convertase subtilisin/kexin type-9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state. <i>Clinical Science</i> , 2015, 128, 379-385.	4.3	39
33	Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2497-2501.	3.6	24
34	Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner. <i>Lipids</i> , 2015, 50, 447-458.	1.7	6
35	Menopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women. <i>Journal of the American Heart Association</i> , 2015, 4, e002258.	3.7	44
36	Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100-Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2686-2693.	2.4	45

#	ARTICLE	IF	CITATIONS
37	Effect of n-3 Fatty Acid Ethyl Esters on Apolipoprotein B-48 Kinetics in Obese Subjects on a Weight-Loss Diet: A New Tracer Kinetic Study in the Postprandial State. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1427-E1435.	3.6	26
38	Dose-Dependent Effects of Rosuvastatin on the Plasma Sphingolipidome and Phospholipidome in the Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2335-E2340.	3.6	59
39	Effect of Niacin on High-Density Lipoprotein Apolipoprotein A-I Kinetics in Statin-Treated Patients With Type 2 Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 427-432.	2.4	28
40	Interrelationships Between the Kinetics of VLDL Subspecies and HDL Catabolism in Abdominal Obesity: A Multicenter Tracer Kinetic Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4281-4290.	3.6	22
41	Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 519-526.	4.4	11
42	Association between skeletal muscle fat content and very-low-density lipoprotein apolipoprotein B-100 transport in obesity: effect of weight loss. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 994-1000.	4.4	9
43	Postprandial effects of a high salt meal on serum sodium, arterial stiffness, markers of nitric oxide production and markers of endothelial function. <i>Atherosclerosis</i> , 2014, 232, 211-216.	0.8	49
44	Plasma Apolipoprotein B-48 Transport in Obese Men: A New Tracer Kinetic Study in the Postprandial State. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E122-E126.	3.6	32
45	The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 369-385.	4.7	32
46	A novel ApoA-I truncation (ApoA-I Mytilene) associated with decreased ApoA-I production. <i>Atherosclerosis</i> , 2014, 235, 470-476.	0.8	11
47	The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: Developing a new framework for future therapies. <i>International Journal of Cardiology</i> , 2013, 168, 1811-1818.	1.7	33
48	Non-alcoholic steatohepatitis-related cirrhosis in a patient with APOB L343V familial hypobetalipoproteinaemia. <i>Clinica Chimica Acta</i> , 2013, 421, 121-125.	1.1	11
49	Omega-3 fatty acid ethyl ester supplementation decreases very-low-density lipoprotein triacylglycerol secretion in obese men. <i>Clinical Science</i> , 2013, 125, 45-51.	4.3	17
50	Dietary fatty acids and lipoprotein metabolism. <i>Current Opinion in Lipidology</i> , 2013, 24, 192-197.	2.7	43
51	Supplementation with n-3 Fatty Acid Ethyl Esters Increases Large and Small Artery Elasticity in Obese Adults on a Weight Loss Diet. <i>Journal of Nutrition</i> , 2013, 143, 437-441.	2.9	17
52	Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism. <i>Journal of Lipid Research</i> , 2012, 53, 1190-1199.	4.2	13
53	Postprandial dyslipidaemia and diabetes. <i>Current Opinion in Lipidology</i> , 2012, 23, 303-309.	2.7	21
54	Apolipoprotein B-100-Containing Lipoprotein Metabolism in Subjects With Lipoprotein Lipase Gene Mutations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 459-466.	2.4	15

#	ARTICLE	IF	CITATIONS
55	Apolipoprotein B-100 and ApoA-II Kinetics as Determinants of Cellular Cholesterol Efflux. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1658-E1666.	3.6	22
56	Effects of Therapeutic Lifestyle Change diets high and low in dietary fish-derived FAs on lipoprotein metabolism in middle-aged and elderly subjects. Journal of Lipid Research, 2012, 53, 1958-1967.	4.2	35
57	Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. Journal of Lipid Research, 2012, 53, 2443-2449.	4.2	15
58	Spokane 2012 Winter Dance Lessons from the Pastâ€”Strategies for the Future 65th Annual SRM Meeting. Ranglands, 2011, 33, 41-42.	1.9	0
59	Altered metabolism of apolipoprotein C-III: a contributor in chronic kidney disease?. Clinical Lipidology, 2011, 6, 247-251.	0.4	0
60	Apolipoprotein A-II and adiponectin as determinants of very low-density lipoprotein apolipoprotein B-100 metabolism in nonobese men. Metabolism: Clinical and Experimental, 2011, 60, 1482-1487.	3.4	10
61	Mechanism of Action of a Peroxisome Proliferator-Activated Receptor (PPAR)-Î³ Agonist on Lipoprotein Metabolism in Dyslipidemic Subjects with Central Obesity. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1568-E1576.	3.6	68
62	Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. Journal of Lipid Research, 2011, 52, 794-800.	4.2	53
63	Genetic determinants of apolipoprotein B-100 kinetics. Current Opinion in Lipidology, 2010, 21, 141-147.	2.7	5
64	Effects of atorvastatin and nâˆ’3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. American Journal of Clinical Nutrition, 2010, 91, 900-906.	4.7	25
65	Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome. Clinical Science, 2010, 118, 79-85.	4.3	15
66	Influence of Simvastatin on apoBâ€”100 Secretion in Nonâ€”Obese Subjects with Mild Hypercholesterolemia. Lipids, 2010, 45, 491-500.	1.7	4
67	The effect of fenofibrate on HDL cholesterol and HDL particle concentration in postmenopausal women on tibolone therapy.. Clinical Endocrinology, 2010, 73, no-no.	2.4	1
68	Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects. Journal of Lipid Research, 2010, 51, 2413-2421.	4.2	13
69	Nonalcoholic Fatty Liver Disease as the Transducer of Hepatic Oversecretion of Very-Low-Density Lipoproteinâ€”Apolipoprotein B-100 in Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1043-1050.	2.4	52
70	Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet. Diabetes Care, 2010, 33, 1134-1139.	8.6	145
71	Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men. Atherosclerosis, 2010, 210, 326-330.	0.8	27
72	Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?. Clinical Chemistry, 2009, 55, 2049-2052.	3.2	63

#	ARTICLE	IF	CITATIONS
73	Very Low Density Lipoprotein Metabolism and Plasma Adiponectin as Predictors of High-Density Lipoprotein Apolipoprotein A-I Kinetics in Obese and Nonobese Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 989-997.	3.6	62
74	Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. <i>Journal of Lipid Research</i> , 2009, 50, 2524-2531.	4.2	62
75	Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome. <i>Diabetes Care</i> , 2009, 32, 2111-2113.	8.6	16
76	Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. <i>Clinical Endocrinology</i> , 2008, 69, 45-51.	2.4	16
77	Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. <i>European Journal of Clinical Investigation</i> , 2008, 38, 743-751.	3.4	56
78	Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. <i>Atherosclerosis</i> , 2008, 197, 139-146.	0.8	38
79	Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. <i>Atherosclerosis</i> , 2008, 197, 732-739.	0.8	42
80	Dose-Dependent Effect of Rosuvastatin on VLDL-Apolipoprotein C-III Kinetics in the Metabolic Syndrome. <i>Diabetes Care</i> , 2008, 31, 1656-1661.	8.6	36
81	Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism. <i>Journal of Lipid Research</i> , 2008, 49, 543-549.	4.2	15
82	Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1831-1837.	2.4	49
83	Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1672-1678.	2.4	137
84	Gender-Specific Differences in the Kinetics of Nonfasting TRL, IDL, and LDL Apolipoprotein B-100 in Men and Premenopausal Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1838-1843.	2.4	43
85	Plasma Apolipoprotein C-III Transport in Centrally Obese Men: Associations with Very Low-Density Lipoprotein Apolipoprotein B and High-Density Lipoprotein Apolipoprotein A-I Metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 557-564.	3.6	62
86	Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor. <i>Journal of Lipid Research</i> , 2008, 49, 2218-2229.	4.2	40
87	Dose-Dependent Regulation of High-Density Lipoprotein Metabolism with Rosuvastatin in the Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 430-437.	3.6	44
88	Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. <i>Clinical Science</i> , 2008, 114, 611-624.	4.3	225
89	HDL metabolism in context: looking on the bright side. <i>Current Opinion in Lipidology</i> , 2008, 19, 395-404.	2.7	24
90	Effect of Weight Loss on LDL and HDL Kinetics in the Metabolic Syndrome. <i>Diabetes Care</i> , 2007, 30, 2945-2950.	8.6	90

#	ARTICLE	IF	CITATIONS
91	Missense Mutations in APOB within the Î²1 Domain of Human APOB-100 Result in Impaired Secretion of ApoB and ApoB-containing Lipoproteins in Familial Hypobetalipoproteinemia. <i>Journal of Biological Chemistry</i> , 2007, 282, 24270-24283.	3.4	66
92	Postprandial Lipoprotein Metabolism in Familial Hypobetalipoproteinemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1474-1478.	3.6	29
93	Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. <i>Journal of Lipid Research</i> , 2007, 48, 1746-1753.	4.2	74
94	The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. <i>Journal of Lipid Research</i> , 2007, 48, 699-708.	4.2	98
95	Blood Concentrations of Enflurane Before, During, and After Hypothermic Cardiopulmonary Bypass. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2007, 21, 218-223.	1.3	14
96	Development of a pharmacodynamic model of murine malaria and antimalarial treatment with dihydroartemisinin. <i>International Journal for Parasitology</i> , 2007, 37, 1569-1576.	3.1	12
97	In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 215-221.	2.6	3
98	Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. <i>American Journal of Clinical Nutrition</i> , 2006, 84, 37-43.	4.7	91
99	Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. <i>Clinical Science</i> , 2006, 111, 193-199.	4.3	28
100	Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. <i>Current Opinion in Lipidology</i> , 2006, 17, 28-36.	2.7	53
101	FISH OILS, PHYTOSTEROLS AND WEIGHT LOSS IN THE REGULATION OF LIPOPROTEIN TRANSPORT IN THE METABOLIC SYNDROME: LESSONS FROM STABLE ISOTOPE TRACER STUDIES. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2006, 33, 877-882.	1.9	13
102	Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 698-702.	4.4	50
103	Plasma phospholipid transfer protein activity, a determinant of HDL kinetics in vivo. <i>Clinical Endocrinology</i> , 2006, 65, 752-759.	2.4	5
104	Effect of an acute hyperinsulinaemic clamp on post-prandial lipaemia in subjects with insulin resistance. <i>European Journal of Clinical Investigation</i> , 2006, 36, 489-496.	3.4	11
105	High-density lipoprotein apolipoprotein A-I kinetics: comparison of radioactive and stable isotope studies. <i>European Journal of Clinical Investigation</i> , 2006, 36, 626-632.	3.4	5
106	Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma. <i>Journal of Lipid Research</i> , 2006, 47, 1274-1280.	4.2	21
107	Effect of Inhibiting Cholesteryl Ester Transfer Protein on the Kinetics of High-Density Lipoprotein Cholesteryl Ester Transport in Plasma. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 884-890.	2.4	36
108	In Vitro Interactions between Piperaquine, Dihydroartemisinin, and Other Conventional and Novel Antimalarial Drugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2883-2885.	3.2	23



#	ARTICLE	IF	CITATIONS
109	Thematic review series: Patient-Oriented Research. What we have learned about VLDL and LDL metabolism from human kinetics studies. <i>Journal of Lipid Research</i> , 2006, 47, 1620-1630.	4.2	47
110	Effects of the Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib on Apolipoprotein B100 Metabolism in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1350-1356.	2.4	68
111	High-Density Lipoprotein (HDL) Transport in the Metabolic Syndrome: Application of a New Model for HDL Particle Kinetics. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 973-979.	3.6	54
112	Apolipoproteins C-III and A-V as Predictors of Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B-100 Kinetics. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 590-596.	2.4	72
113	Role of the Estrogen and Progestin in Hormonal Replacement Therapy on Apolipoprotein A-I Kinetics in Postmenopausal Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 385-391.	2.4	34
114	Thematic review series: Patient-Oriented Research. Design and analysis of lipoprotein tracer kinetics studies in humans. <i>Journal of Lipid Research</i> , 2006, 47, 1607-1619.	4.2	55
115	Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 406-413.	4.4	125
116	Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?. <i>Clinical Endocrinology</i> , 2005, 63, 650-656.	2.4	5
117	High-density Lipoprotein Apolipoprotein A-I Kinetics in Obesity. <i>Obesity</i> , 2005, 13, 1008-1016.	4.0	42
118	Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men. <i>Clinical Biochemistry</i> , 2005, 38, 806-812.	1.9	7
119	Adipocytokines and VLDL Metabolism: Independent Regulatory Effects of Adiponectin, Insulin Resistance, and Fat Compartments on VLDL Apolipoprotein B-100 Kinetics?. <i>Diabetes</i> , 2005, 54, 795-802.	0.6	105
120	TRL, IDL, and LDL Apolipoprotein B-100 and HDL Apolipoprotein A-I Kinetics as a Function of Age and Menopausal Status. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1691-1696.	2.4	37
121	Liver Dysfunction and Steatosis in Familial Hypobetalipoproteinemia. <i>Clinical Chemistry</i> , 2005, 51, 266-269.	3.2	35
122	A Novel Inhibitor of Oxidosqualene:Lanosterol Cyclase Inhibits Very Low-density Lipoprotein Apolipoprotein B100 (ApoB100) Production and Enhances Low-Density Lipoprotein ApoB100 Catabolism Through Marked Reduction in Hepatic Cholesterol Content. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2608-2614.	2.4	23
123	Adiponectin and other Adipocytokines as Predictors of Markers of Triglyceride-Rich Lipoprotein Metabolism. <i>Clinical Chemistry</i> , 2005, 51, 578-585.	3.2	93
124	Complete Deficiency of the Low-Density Lipoprotein Receptor Is Associated With Increased Apolipoprotein B-100 Production. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 560-565.	2.4	74
125	59th Society for Range Management Annual Meeting Management Annual Meeting. <i>Rangelands</i> , 2005, 27, 22-23.	1.9	0
126	The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 361-369.	3.4	60



#	ARTICLE	IF	CITATIONS
127	The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2005, 1738, 10-18.	2.4	8
128	Disposition of Artesunate and Dihydroartemisinin after Administration of Artesunate Suppositories in Children from Papua New Guinea with Uncomplicated Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2966-2972.	3.2	50
129	Interrelationships Between Human Apolipoprotein A-I and Apolipoproteins B-48 and B-100 Kinetics Using Stable Isotopes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1703-1707.	2.4	41
130	ATP-Binding Cassette Transporter C8 Gene As a Determinant of Apolipoprotein B-100 Kinetics in Overweight Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2188-2191.	2.4	28
131	Lipid Disorders and Mutations in the APOB Gene. <i>Clinical Chemistry</i> , 2004, 50, 1725-1732.	3.2	191
132	In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy. <i>Journal of Lipid Research</i> , 2004, 45, 1459-1467.	4.2	25
133	Dietary Hydrogenated Fat Increases High-Density Lipoprotein apoA-I Catabolism and Decreases Low-Density Lipoprotein apoB-100 Catabolism in Hypercholesterolemic Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1092-1097.	2.4	105
134	A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. <i>Kidney International</i> , 2004, 65, 1064-1075.	5.2	30
135	Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. <i>Diabetologia</i> , 2004, 47, 837-843.	6.3	31
136	Dyslipidemia in Visceral Obesity. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 227-246.	2.2	94
137	Adipose tissue compartments and insulin resistance in overweight-obese Caucasian men. <i>Diabetes Research and Clinical Practice</i> , 2004, 63, 77-85.	2.8	22
138	Smooth muscle cell biglycan overexpression results in increased lipoprotein retention on extracellular matrix: implications for the retention of lipoproteins in atherosclerosis. <i>Atherosclerosis</i> , 2004, 177, 29-35.	0.8	48
139	Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies. <i>Clinical Science</i> , 2004, 107, 221-232.	4.3	42
140	Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotope and modelling methods. <i>Clinical Science</i> , 2004, 107, 233-249.	4.3	42
141	Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies. <i>Clinical Biochemist Reviews</i> , 2004, 25, 31-48.	3.3	7
142	Four novel mutations in APOB causing heterozygous and homozygous familial hypobetalipoproteinemia. <i>Human Mutation</i> , 2003, 22, 178-178.	2.5	18
143	Genes, environment and Oji-Cree type 2 diabetes. <i>Clinical Biochemistry</i> , 2003, 36, 163-170.	1.9	52
144	Comparison of intraperitoneal and posterior subcutaneous abdominal adipose tissue compartments as predictors of VLDL apolipoprotein B-100 kinetics in overweight/obese men. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, 202-206.	4.4	5

#	ARTICLE	IF	CITATIONS
145	Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without type 2 diabetes mellitus. <i>Clinical Endocrinology</i> , 2003, 58, 415-420.	2.4	37
146	Fat Compartments and Apolipoprotein B-100 Kinetics in Overweight/Obese Men. <i>Obesity</i> , 2003, 11, 152-159.	4.0	18
147	Plasma Markers of Cholesterol Homeostasis and Apolipoprotein B-100 Kinetics in the Metabolic Syndrome. <i>Obesity</i> , 2003, 11, 591-596.	4.0	27
148	Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. <i>International Journal of Obesity</i> , 2003, 27, 862-865.	3.4	47
149	Hepatocyte ApoB-Containing Lipoprotein Secretion Is Decreased by the Grapefruit Flavonoid, Naringenin, via Inhibition of MTP-Mediated Microsomal Triglyceride Accumulation. <i>Biochemistry</i> , 2003, 42, 1283-1291.	2.5	97
150	Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 136-141.	3.4	50
151	Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome. <i>Diabetes</i> , 2003, 52, 803-811.	0.6	207
152	Toxicity Related to Chloroquine Treatment of Resistant Vivax Malaria. <i>Annals of Pharmacotherapy</i> , 2003, 37, 526-529.	1.9	10
153	Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans. <i>Journal of Lipid Research</i> , 2003, 44, 1341-1348.	4.2	28
154	Waist circumference, waist-to-hip ratio and body mass index as predictors of adipose tissue compartments in men. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 441-447.	0.5	198
155	Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB. <i>Journal of Lipid Research</i> , 2003, 44, 943-952.	4.2	27
156	Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. <i>Journal of Lipid Research</i> , 2003, 44, 1192-1198.	4.2	45
157	Relationships between cholesterol homeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. <i>Clinical Science</i> , 2003, 104, 383.	4.3	32
158	Vascular function of forearm microcirculation in postmenopausal women with type 2 diabetes: potential benefit of hormone replacement therapy?. <i>Climacteric</i> , 2003, 6, 31-37.	2.4	1
159	Metabolism of ApoA-I as Lipid-Free Protein or as Component of Discoidal and Spherical Reconstituted HDLs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1912-1917.	2.4	43
160	HNF-1 $\alpha$ G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree community. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 4614-4619.	7.1	110
161	Lipolytically Modified Triglyceride-Enriched HDLs Are Rapidly Cleared From the Circulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 483-487.	2.4	84
162	Inhibition of the Apical Sodium-Dependent Bile Acid Transporter Reduces LDL Cholesterol and ApoB by Enhanced Plasma Clearance of LDL ApoB. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1884-1891.	2.4	58

#	ARTICLE	IF	CITATIONS
163	ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. <i>Journal of Lipid Research</i> , 2002, 43, 1969-1977.	4.2	85
164	Inhibition of hepatocyte apoB secretion by naringenin. <i>Journal of Lipid Research</i> , 2002, 43, 1544-1554.	4.2	65
165	Apolipoprotein B Metabolism: Tracer Kinetics, Models, and Metabolic Studies. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2002, 39, 89-137.	6.1	37
166	Effect of Atorvastatin on High-Density Lipoprotein Apolipoprotein A-I Production and Clearance in the New Zealand White Rabbit. <i>Circulation</i> , 2002, 106, 2955-2960.	1.6	37
167	Regulatory Effects of HMG CoA Reductase Inhibitor and Fish Oils on Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Male Subjects With Dyslipidemia. <i>Diabetes</i> , 2002, 51, 2377-2386.	0.6	162
168	Shifting the LDL-receptor paradigm in familial hypercholesterolemia: novel insights from recent kinetic studies of apolipoprotein B-100 metabolism. <i>Atherosclerosis Supplements</i> , 2002, 2, 1-4.	1.2	9
169	Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentration. <i>Metabolism: Clinical and Experimental</i> , 2002, 51, 1041-1046.	3.4	129
170	Adipose tissue compartments and the kinetics of very[ndash ]low-density lipoprotein apolipoprotein B-100 in non-obese men. <i>Metabolism: Clinical and Experimental</i> , 2002, 51, 1206-1210.	3.4	7
171	Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia. <i>Journal of Lipid Research</i> , 2002, 43, 1464-1471.	4.2	22
172	Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. <i>European Journal of Clinical Investigation</i> , 2002, 32, 429-436.	3.4	82
173	Effect of Simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolaemia. <i>European Journal of Clinical Investigation</i> , 2002, 32, 493-499.	3.4	10
174	Glucose and lactate turnover in adults with falciparum malaria: effect of complications and antimalarial therapy. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2002, 96, 411-417.	1.8	21
175	Idiopathic hypoalbuminemia explained by reduced synthesis rate and an increased catabolic rate. <i>Clinical Biochemistry</i> , 2002, 35, 545-553.	1.9	7
176	Chylomicron remnant metabolism in familial hypercholesterolaemia studied with a stable isotope breath test. <i>Atherosclerosis</i> , 2001, 157, 519-523.	0.8	23
177	HDL kinetics, fish oils and diabetes. <i>Atherosclerosis</i> , 2001, 159, 243-244.	0.8	1
178	Preliminary experience with a new stable isotope breath test for chylomicron remnant metabolism: a study in central obesity. <i>Clinical Science</i> , 2001, 101, 683.	4.3	7
179	Elevated apolipoprotein B-48 and remnant-like particle-cholesterol in heterozygous familial hypercholesterolaemia. <i>European Journal of Clinical Investigation</i> , 2001, 31, 113-117.	3.4	36
180	Biglycan, a Vascular Proteoglycan, Binds Differently to HDL <sub>2</sub> and HDL <sub>3</sub>. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 129-135.	2.4	44

#	ARTICLE	IF	CITATIONS
181	The Contribution of Intraabdominal Fat to Gender Differences in Hepatic Lipase Activity and Low/High Density Lipoprotein Heterogeneity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2831-2837.	3.6	87
182	Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. <i>British Journal of Clinical Pharmacology</i> , 2000, 49, 223-230.	2.4	65
183	Effects of ApoE Genotype on ApoB-48 and ApoB-100 Kinetics With Stable Isotopes in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1807-1810.	2.4	48
184	Kinetics of veryâ€‘low-density lipoprotein apolipoprotein B-100 in normolipidemic subjects: Pooled analysis of stable-isotope studies. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 1204-1210.	3.4	29
185	Pulse-chase studies: Estimating apolipoprotein secretion and post-translational degradation rates. <i>Atherosclerosis</i> , 2000, 151, 286-287.	0.8	0
186	Chylomicron remnant metabolism studied with a new stable isotope breath test in centrally obese subjects. <i>Atherosclerosis</i> , 2000, 151, 95-96.	0.8	1
187	The role of the LDL receptor in apolipoprotein B secretion. <i>Journal of Clinical Investigation</i> , 2000, 105, 521-532.	8.2	213
188	Atorvastatin Improves Postprandial Lipoprotein Metabolism in Normolipidemic Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4224-4230.	3.6	42
189	ApoB100 Secretion From HepG2 Cells is Decreased by the ACAT Inhibitor CI-1011. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 939-949.	2.4	56
190	Lipoprotein Lipase Enhances the Binding of Native and Oxidized Low Density Lipoproteins to Versican and Biglycan Synthesized by Cultured Arterial Smooth Muscle Cells. <i>Journal of Biological Chemistry</i> , 1999, 274, 34629-34636.	3.4	85
191	Human Apolipoprotein (Apo) B-48 and ApoB-100 Kinetics With Stable Isotopes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2966-2974.	2.4	98
192	Heterogeneous activity in vitro of vitamin A (retinol) in combination with novel and established antimalarial drugs. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1999, 93, 550-551.	1.8	11
193	Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. <i>Journal of Clinical Investigation</i> , 1999, 103, 1191-1199.	8.2	196
194	Reduction in Visceral Adipose Tissue Is Associated with Improvement in Apolipoprotein B-100 Metabolism in Obese Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2854-2861.	3.6	78
195	Low-density lipoprotein-apolipoprotein B metabolism following apheresis: Simulation studies of mass changes and tracer kinetics. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 478-483.	3.4	11
196	SAAM II: Simulation, analysis, and modeling software for tracer and pharmacokinetic studies. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 484-492.	3.4	401
197	Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol. <i>Lipids and Lipid Metabolism</i> , 1998, 1393, 63-79.	2.6	21
198	Metabolic modes of action of the statins in the hyperlipoproteinemias. <i>Atherosclerosis</i> , 1998, 141, 203-207.	0.8	60

#	ARTICLE	IF	CITATIONS
199	Inhibition of HMG-CoA Reductase by Atorvastatin Decreases Both VLDL and LDL Apolipoprotein B Production in Miniature Pigs. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2589-2600.	2.4	90
200	Plasma Kinetics of Cholesteryl Ester Transfer Protein in the Rabbit. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 203-210.	2.4	21
201	Decreased Production and Increased Catabolism of Apolipoprotein B-100 in Apolipoprotein B-67/B-100 Heterozygotes. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 881-888.	2.4	36
202	Apoprotein B-100 Production Is Decreased in Subjects Heterozygous for Truncations of Apoprotein B. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 71-80.	2.4	65
203	Relationships of plasma and hepatic variables with rates of plasma low-density lipoprotein apolipoprotein B metabolism in baboons fed low- and high-fat diets. Metabolism: Clinical and Experimental, 1995, 44, 1058-1066.	3.4	5
204	Inhibition of hepatic ACAT decreases ApoB secretion in miniature pigs fed a cholesterol-free diet.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 1498-1508.	3.9	86
205	Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia. The Clinical Investigator, 1993, 71, 939-46.	0.6	28
206	Metabolic regulation of plasma apolipoprotein E by estrogen and progesterone in the baboon (Papio Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.4	35